Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scientists seek to unravel hidden subtypes of Sepsis-Linked lung failure

NCT ID NCT07281911

Knowledge-focused Sponsor: Hospital Universitari Vall d'Hebron Research Institute Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Aug 28, 2026 · Updated 2 times

Summary

This study will closely monitor 180 adults with sepsis-related acute respiratory distress syndrome (ARDS) who are on breathing machines. Researchers will take fluid samples from the lungs and blood at several time points to measure inflammation and injury markers. The goal is to identify distinct biological and physical patterns of the disease, which could eventually help doctors tailor treatments to each patient's specific condition.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could identify distinct subtypes of sepsis-related ARDS, paving the way for more personalized treatments in the future.
What could go wrong
This is an early observational study, not a treatment trial. It will not directly test any therapy, and the findings may not lead to immediate clinical changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 145 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Mar 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants are adult ICU patients admitted with sepsis or septic shock who require invasive mechanical ventilation within 72 hours of sepsis diagnosis. These patients represent a high-risk population for sepsis-associated lung injury and ARDS, with dynamic biological and physiological changes occurring during the earliest phase of critical illness. The study follows participants for the first 96 hours after sepsis diagnosis to capture these early trajectories.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria * Age ≥18 years. * Sepsis or septic shock according to Sepsis-3 criteria. * Requirement for invasive mechanical ventilation within 72 hours of sepsis diagnosis. * Written informed consent provided by the participant or a legally authorized representative. Exclusion Criteria * Pregnancy. * Previous lung transplantation. * Contraindication to bronchoscopy or bronchoalveolar lavage (BAL).Inability to complete at least two BAL procedures during the 96-hour study period. * Expected death within 24 hours or limitation of life-sustaining treatment at enrollment. * Written informed consent not obtained.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute hypoxemic respiratory failure are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute lung injury acute respiratory distress syndrome acute respiratory failure infectious disease with sepsis respiratory failure Sepsis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute hypoxemic respiratory failure ARDS (acute respiratory distress syndrome) Sepsis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hospital Universitari Vall d'Hebron

    Barcelona, Barcelona, 08035, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.